X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to support the advancement of an Industry-leading, comprehensive platform of RNA technologies and a first-in-class portfolio of programmable RNA-based therapies.
Lead Product(s): RNA-based therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 26, 2023
Details:
As part of its launch, Orbital and Beam Therapeutics have entered into a license and research collaboration under which Orbital and Beam have each granted the other access to respective RNA technology and non-viral delivery technology.
Lead Product(s): RNA-based Medicine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: Beam Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 07, 2022
Details:
RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.
Lead Product(s): RNA-based Vaccine
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Beam Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
